- Home
- CKPT vs ALDF Comparison
CKPT vs ALDF Comparison
Compare CKPT & ALDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CKPT
- ALDF
- Stock Information
- Founded
- CKPT 2014
- ALDF 2024
- Country
- CKPT United States
- ALDF United States
- Employees
- CKPT N/A
- ALDF N/A
- Industry
- CKPT Biotechnology: Pharmaceutical Preparations
- ALDF
- Sector
- CKPT Health Care
- ALDF
- Exchange
- CKPT Nasdaq
- ALDF NYSE
- Market Cap
- CKPT 335.9M
- ALDF 302.7M
- IPO Year
- CKPT 2017
- ALDF 2024
- Fundamental
- Price
- CKPT $4.04
- ALDF $10.09
- Analyst Decision
- CKPT Buy
- ALDF
- Analyst Count
- CKPT 3
- ALDF 0
- Target Price
- CKPT $4.33
- ALDF N/A
- AVG Volume (30 Days)
- CKPT 1.7M
- ALDF 75.2K
- Earning Date
- CKPT 05-09-2025
- ALDF 01-01-0001
- Dividend Yield
- CKPT N/A
- ALDF N/A
- EPS Growth
- CKPT N/A
- ALDF N/A
- EPS
- CKPT N/A
- ALDF N/A
- Revenue
- CKPT $41,000.00
- ALDF N/A
- Revenue This Year
- CKPT $102,182.93
- ALDF N/A
- Revenue Next Year
- CKPT $351.71
- ALDF N/A
- P/E Ratio
- CKPT N/A
- ALDF $80.00
- Revenue Growth
- CKPT N/A
- ALDF N/A
- 52 Week Low
- CKPT $1.38
- ALDF $9.90
- 52 Week High
- CKPT $4.50
- ALDF $10.69
- Technical
- Relative Strength Index (RSI)
- CKPT 63.60
- ALDF N/A
- Support Level
- CKPT $3.94
- ALDF N/A
- Resistance Level
- CKPT $4.06
- ALDF N/A
- Average True Range (ATR)
- CKPT 0.05
- ALDF 0.00
- MACD
- CKPT -0.03
- ALDF 0.00
- Stochastic Oscillator
- CKPT 83.33
- ALDF 0.00
About CKPT Checkpoint Therapeutics Inc.
Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in the USA. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its licensed portfolio of antibodies includes targeting programmed cell death-ligand 1 (PD-L1), glucocorticoid-induced TNFR-related protein (GITR) and carbonic anhydrase IX (CAIX). The company is evaluating its small-molecule, targeted anti-cancer agent, olafertinib, a third-generation epidermal growth factor receptor (EGFR) inhibitor, as a potential new treatment for patients with EGFR mutation-positive non-small cell lung cancer.
About ALDF ALDEL FINL II INC
Aldel Financial II Inc is a Shell Company with various businesses.